Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $21.00 price target on the biotechnology company’s stock.

Several other brokerages also recently commented on ATNM. StockNews.com raised Actinium Pharmaceuticals from a sell rating to a hold rating in a report on Monday. HC Wainwright reaffirmed a buy rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday. Finally, Maxim Group upped their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a report on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $25.72.

Actinium Pharmaceuticals Stock Up 4.2 %

NYSEAMERICAN:ATNM opened at $7.69 on Tuesday. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $9.86. The firm has a market capitalization of $226.09 million, a PE ratio of -4.20 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter. As a group, sell-side analysts predict that Actinium Pharmaceuticals will post -1.87 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Brandywine Global Investment Management LLC bought a new stake in Actinium Pharmaceuticals during the 3rd quarter valued at approximately $1,033,000. Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the period. Finally, Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth approximately $78,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.